+33 1 76 70 47 90
/
creativ@creativ-ceutical.com
Home
Who We Are
About Us
Strategic Management Board
What we do
Value & Market Access
Payer Landscape
Pricing Research
Early Dialog
PRMA Strategy
Evidence Generation
Decision Sciences & Outcomes Research
Modeling
HTA submission
Data Analytics
Evidence Synthesis
Patient-Centered Research
Real World Evidence
Exclusive Customized Consulting
Biotech Strategic Consulting
Corporate Strategic Consulting
Expertise
Senior Management
Partnerships
Japan
Publications
News & Events
Careers
Contact
Home
Who We Are
About Us
Strategic Management Board
What we do
Value & Market Access
Payer Landscape
Pricing Research
Early Dialog
PRMA Strategy
Evidence Generation
Decision Sciences & Outcomes Research
Modeling
HTA submission
Data Analytics
Evidence Synthesis
Patient-Centered Research
Real World Evidence
Exclusive Customized Consulting
Biotech Strategic Consulting
Corporate Strategic Consulting
Expertise
Senior Management
Partnerships
Japan
Publications
News & Events
Careers
Contact
Escitalopram treatment improves Quality of Life of Generalised Anxiety Disorder patients measured by SF-36
Home
Publications
Escitalopram treatment improves Quality of Life of Generalised Anxiety Disorder patients measured by SF-36
Back Home
Escitalopram treatment improves Quality of Life of Generalised Anxiety Disorder patients measured by SF-36
2005 ISOQOL
Jorgensern, T. | Despiegel, N. | Francois, C. |
Volume: , Issue: , Pages: ,
The website uses cookies.
Learn More
Ok
